Oramed Pharmaceuticals INC

Oramed Pharmaceuticals Inc. announced amendments to its bylaws regarding stockholder action by written consent and an extension for Scilex Holding Company's payment obligations on outstanding promissory notes.

Oramed Pharmaceuticals Inc. announced the completion of its sale of Oratech Pharma to Lifeward Ltd. and a concurrent $9 million investment in Lifeward.

Oramed Pharmaceuticals Inc. has announced a strategic transaction to transfer its oral drug delivery technology to Lifeward Ltd., becoming a significant shareholder and investor in the medical robotics company.

Oramed Pharmaceuticals announced an $18 million payment from Scilex Holdings, bringing total returns to $118 million, and approved a $0.25 per share cash dividend.

Leonard Sanks has resigned from the Board of Directors of Oramed Pharmaceuticals Inc., effective January 1, 2026, after 18 years of service.

Oramed Pharmaceuticals Inc. announced the completion of the repurchase of all remaining Scilex warrants, totaling $28.5 million in aggregate payments.

Oramed Pharmaceuticals Inc. reported a significant net income of $38.3 million for Q1 2026, a substantial turnaround from a net loss in the prior year, primarily driven by substantial gains from its investment portfolio.

Oramed Pharmaceuticals reported a significant net income for Q3 2025, driven by substantial revaluation gains from its Scilex and Alpha Tau investments, while terminating its oral insulin joint venture with HTIT and planning a smaller clinical trial.

Oramed Pharmaceuticals reports mixed Q2 2025 results, with a significant increase in net income driven by investment revaluations, despite a delayed oral insulin joint venture and increased R&D spending.

Oramed Pharmaceuticals reports a net loss for Q1 2025, but sees revenue increase due to the HTIT License Agreement and progresses with strategic real estate investments.

Oramed Pharmaceuticals reported its Q3 2024 results, highlighting a strategic review process and ongoing financial activities, including a significant transaction with Scilex Holding Company.

Oramed Pharmaceuticals reported a net income of $10.7 million for the second quarter of 2024, primarily driven by financial income from its investment in Scilex Holding Company, while research and development expenses decreased.

Oramed Pharmaceuticals Inc. reports a significant net income swing in 2025, driven by strategic investment revaluations and a new path for its oral insulin program.

Oramed Pharmaceuticals Inc. filed an amendment to its 2024 Annual Report on Form 10-K to correct disclosures related to Named Executive Officer compensation and security ownership, reflecting revised NEO qualifications and updated certifications.

Oramed Pharmaceuticals Inc. files its 10-K, detailing financial results for 2024 and outlining strategic initiatives including a joint venture for oral insulin development and real estate investments.

Oramed Pharmaceuticals has amended consulting and employment agreements with key personnel and filed its annual report, detailing financial results and strategic updates.

Joshua Hexter, COO & CBO of Oramed Pharmaceuticals, reported transactions involving the sale of common stock and the exercise of stock options.

Oramed Pharmaceuticals CFO Avraham Gabay sold 73,360 shares of common stock on July 1, 2026, pursuant to a Rule 10b5-1 trading plan.

Oramed Pharmaceuticals CEO Nadav Kidron disposed of 44,818 shares of common stock to cover tax withholding obligations related to RSU vesting.

Oramed Pharmaceuticals' Chief Scientific Officer, Miriam Kidron, disposed of 435,084 shares of common stock to cover tax withholding obligations related to RSU vesting.

Oramed Pharmaceuticals' Chief Scientific Officer, Miriam Kidron, received a grant of 119,558 Restricted Stock Units, vesting quarterly starting April 2026.

Oramed Pharmaceuticals Inc. CEO Nadav Kidron received a grant of 167,005 Restricted Stock Units, which will vest quarterly starting April 1, 2026.

Oramed Pharmaceuticals Inc. announced its 2025 Annual Meeting of Stockholders to be held on August 19, 2025, seeking approval for director re-elections, auditor ratification, and an increase in its stock incentive plan shares.

Oramed Pharmaceuticals will hold its annual meeting of stockholders on August 1, 2024, to vote on director re-elections, executive compensation, and auditor ratification.

Oramed Pharmaceuticals Inc. reports changes in beneficial ownership of Nano Dimension Ltd. ordinary shares, including option and put option transactions.

Oramed Pharmaceuticals has increased its stake in Nano Dimension to 7.2% and publicly declared opposition to the company's proposed transaction with Infinite Epigenetics.

Oramed Pharmaceuticals has filed a Schedule 13D reporting a 49.9% beneficial ownership stake in Lifeward Ltd. following the acquisition of Oratech Pharma and a private placement of convertible notes.

Oramed Pharmaceuticals Inc. has increased its beneficial ownership in Nano Dimension Ltd. to 5.2%, expressing strong dissatisfaction with the issuer's management and strategic direction.

Oramed Pharmaceuticals Inc. and CEO Nadav Kidron have jointly acquired a 5.0% stake in Nano Dimension Ltd., signaling intent to engage with management on strategic and governance matters.

Nadav Kidron, a key figure at Oramed Pharmaceuticals Inc., has increased his beneficial ownership to 7.6% of the company's common stock, primarily through equity grants.

BML Investment Partners, L.P. has reported a beneficial ownership of 2.5% in Oramed Pharmaceuticals Inc., holding 1,026,269 shares.

Aquamarine Financial (Cayman) Ltd has reported beneficial ownership of 2,047,652 shares, representing 5.06% of Oramed Pharmaceuticals Inc.'s common stock, as of January 14, 2026.

Oramed Pharmaceuticals Inc. has disclosed a 4.9% beneficial ownership stake in Scilex Holding Co., primarily through warrants and convertible notes.

BML Investment Partners, L.P. and Braden M. Leonard have reported beneficial ownership of 8.3% of Oramed Pharmaceuticals Inc. common stock.

Oramed Pharmaceuticals Inc. has filed an amended Schedule 13G, disclosing a 9.9% beneficial ownership stake in Scilex Holding Co.

Oramed Pharmaceuticals Inc. has disclosed a 9.9% beneficial ownership stake in Scilex Holding Co, primarily through exercisable warrants.